grant
Biofluid Core
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Sept 2019Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY20254 repeat tau pathology4 repeats tau4 repeats tauopathies4R tau4R tauopathiesAD dementiaAD related dementiaADRDAcademiaAddressAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAlzheimers DementiaAmentiaAstroproteinAutopsyBiologicalBiological MarkersBloodBlood PlasmaBlood Reticuloendothelial SystemC9ORF72CatalogingCerebrospinal FluidClinicalClinical TrialsCollectionCommunitiesCorticodentatonigral degeneration with neuronal achromasiaDataData BasesData Management and Analysis CoreData Management and Statistical Analysis CoreData Management and Statistical CoreData SetDatabasesDegenerative Neurologic DisordersDementiaDiagnosisDiagnosticDipeptidesDiseaseDisease ProgressionDisorderDysfunctionEarly DiagnosisEarly treatmentEnrollmentEquipment and supply inventoriesExonsFTD TDPFTD TDP43FTLDFTLD TDPFTLD TDP43FTLD TDP43 proteinopathyFrontal Temporal Lobar DegenerationFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationFunctional disorderFundingGFA-ProteinGFAPGene ExpressionGlial Fibrillary Acid ProteinGlial Fibrillary Acidic ProteinGlial Intermediate Filament ProteinHigh PrevalenceIndividualIndustryInternationalInventoryInvestigatorsIsoformsL-ThreonineLeadershipLifeLightLiquid substanceMT-bound tauMeasurableMeasuresMonitorNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsPC cell-derived growth factorPCDGFPGRN genePGRN proteinParticipantPathogenesisPathologicPatientsPhenocopyPhosphorylationPhotoradiationPhysiopathologyPlasmaPlasma SerumPopulationPredispositionPreventionPrimary Senile Degenerative DementiaPrognostic MarkerProgranulinProgressive Supranuclear OphthalmoplegiaProgressive Supranuclear PalsyProtein IsoformsProtein PhosphorylationProteinsProteomeProteomicsPublicationsRecommendationResearchResearch PersonnelResearch ResourcesResearchersResourcesReticuloendothelial System, Serum, PlasmaRiskRoleSamplingScientific PublicationSensitivity and SpecificitySpecificityStagingStandardizationSteele-Richardson-Olszewski DiseaseSteele-Richardson-Olszewski SyndromeSurrogate MarkersSusceptibilitySyndromeTAR DNA binding protein 43 kDa pathologyTAR DNA binding protein 43 pathologyTAR DNA binding protein of 43 proteinopathyTAR DNA-binding protein 43TDP-43TDP43TDP43 associated neurodegenerationTDP43 associated neurodegenerative diseaseTDP43 associated pathologiesTDP43 induced neurodegenerationTDP43 neurodegenerationTDP43 neurodegenerative diseaseTDP43 neuropathologyTDP43 pathogenesisTDP43 pathologyTDP43 proteinopathyTDP43 related neurodegenerationTDP43 related pathologyTauopathiesTechniquesTestingTherapeuticThreonineTrans active response DNA binding protein 43 pathologyTrans active response DNA binding protein of 43 kDa proteinopathyVisitabnormally aggregated tau proteinautosomal dominant mutationbehavioral variant FTDbehavioral variant frontotemporal degenerationbehavioral variant frontotemporal dementiabio-markersbiobankbiologicbiologic markerbiomarkerbiomarker developmentbiomarker discoverybiomarker identificationbiorepositorybvFTDcandidate biomarkercandidate markercarrier statuscerebral spinal fluidchromosome 9 open reading frame 72clinical diagnosiscohortcortical basal degenerationcorticobasal degenerationcostdata basedata managementdata sharingdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdepositorydetection assaydevelop therapyearly detectionearly therapyenrollextracellular vesiclesfilamentous tau inclusionfluidfour repeat tau pathologyfour repeat tau tauopathiesfour repeats taufour repeats tauopathiesfrontotemporal lobar degeneration caused by TDP43 proteinopathyfrontotemporal lobar degeneration with TDP43 pathologyfrontotemporal lobar degeneration with TDP43 proteinopathygranulin precursoridentification of biomarkersidentification of new biomarkersimprovedintervention developmentintervention effectliquidmarker identificationmedically under servedmedically underservedmicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule bound taumicrotubule-bound taumutation carriernecropsyneurodegenerative illnessneurofilamentneuropathologicneuropathologic tauneuropathologicalneuropathological tauneuropathologynew approachesnovelnovel approachesnovel strategiesnovel strategyp-taup-τpaired helical filament of taupathophysiologypharmacodynamic biomarkerpharmacodynamic markerphospho-tauphospho-τphosphorylated taupost-translational modification of taupostmortemposttranslational modification of taupotential biological markerpotential biomarkerpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprimary degenerative dementiaprognostic biomarkerprognostic indicatorprogranulin geneprogranulin proteinprotein TDP-43protein TDP43repositoryresponse biomarkerresponse markerssample collectionself-aggregate tausenile dementia of the Alzheimer typesocial rolespecimen collectionspinal fluidstandard measuresurrogate bio-markerssurrogate biomarkerstautau PHFtau Proteinstau accumulationtau aggregatetau aggregationtau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau fibrillizationtau filamenttau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neurofibrillary tangletau neuropathologytau oligomertau paired helical filamenttau pathologytau pathophysiologytau phosphorylationtau polymerizationtau posttranslational modificationtau proteinopathytau related neurodegenerationtau-1tau-induced pathologytau-tau interactiontauopathic neurodegenerative disordertauopathytherapeutic agent developmenttherapeutic developmenttherapy developmenttooltrans active response DNA binding protein 43 kDa pathologytrans active response DNA binding protein 43 proteinopathytreatment developmenttreatment trialunder served communityunderserved communityτ Proteinsτ aggregationτ phosphorylation
Description preview
ABSTRACT – ALLFTD2: BIOFLUID CORE
FTLD encompasses a group of fatal neurodegenerative disorders primarily neuropathologically characterized by
the aggregation of tau or TDP-43 proteins. No approved treatment for any FTLD syndrome exists owing, in part,
to our incomplete understanding of FTLD pathogenesis and to the lack of diagnostic,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click